ReviewCurrent osteoporosis reports2021
Osteocytes and Estrogen Deficiency.
Review in Current osteoporosis reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 2 syntheses or guidelines pooled it, 78 citations in OpenAlex.
- Comparison of the Efficacy of Denosumab and Alendronate in Improving Bone Mineral Density in Osteoporosis Patients and High-Risk Populations: A Systematic Review and Meta-Analysis.Clinical drug investigation · 2026Pooled it
- Effect of Tai Chi exercise on bone health and fall prevention in postmenopausal women: a meta-analysis.Journal of orthopaedic surgery and research · 2024Pooled it
- Article
- Osteocyte-vascular Interactions in Bone Physiology and Pathology.Current osteoporosis reports · 2026Review
- Estrogen deficiency as a common driver and integrative mechanism in osteoporosis‑osteoarthritis comorbidity (Review).Molecular medicine reports · 2026Review
- HALP score-adjusted FRAXplus tool effectively predicts hip fracture risk in elderly women with type 2 diabetes mellitus.BMC endocrine disorders · 2026Article
- Alzheimer's Disease Risk Factor APOE4 Exerts Dimorphic Effects on Female Bone.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Pilose Antler Protein Extract Alleviates Osteoporosis and Is Associated with Activation of the Wnt/β-Catenin Signaling Pathway.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Osteocyte Cell-Cell Communication Within and Beyond Bone.Current osteoporosis reports · 2026Review
- Bone tissue regeneration: role of osteocyte mechanosensing and mechanotransduction.Stem cells translational medicine · 2026Review
- Exploring neuronal mechanisms of osteosarcopenia in older adults.The Journal of physiology · 2026Review
- Modulation of tocotrienol's bone effects by osteocytes: a perspective.Frontiers in pharmacology · 2026Article
- Mathematical modeling of bone remodeling after surgical menopause.Frontiers in systems biology · 2026Article
- Osteocyte Neuropeptide Y Aggravates Bone Loss in OVX Mice by Inhibiting Preosteoclast Proliferation and PDGF-BB-Induced Type H Vessel Formation Through PI3K/Akt Signaling Pathway.Calcified tissue international · 2025Article
- Article
- Plasma proteomic profiles reveal proteins and three characteristic patterns associated with osteoporosis: A prospective cohort study.Journal of advanced research · 2025Article
- Identification and validation ofBiomolecules & biomedicine · 2025Article
- Hip Fractures: Clinical, Biomaterial and Biomechanical Insights into a Common Health Challenge.Bioengineering (Basel, Switzerland) · 2025Review
- Palm Tocotrienol Preserves Trabecular Osteocyte Indices and Modulates the Expression of Osteocyte Markers in Ovariectomized Rats.Biomedicines · 2025Article
- Association of visceral fat metabolic score with bone mineral density and osteoporosis: a NHANES cross-sectional study.Journal of health, population, and nutrition · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewPostmenopausal osteoporosis reduces circulating estrogen levels, which leads to osteoclast resorption, bone loss, and fracture. This review addresses emerging evidence that osteoporosis is not simply a disease of bone loss but that mechanosensitive osteocytes that regulate both osteoclasts and osteoblasts are also impacted by estrogen deficiency. RECENT
findingsAt the onset of estrogen deficiency, the osteocyte mechanical environment is altered, which coincides with temporal changes in bone tissue composition. The osteocyte microenvironment is also altered, apoptosis is more prevalent, and hypermineralization occurs. The mechanobiological responses of osteocytes are impaired under estrogen deficiency, which exacerbates osteocyte paracrine regulation of osteoclasts. Recent research reveals changes in osteocytes during estrogen deficiency that may play a critical role in the etiology of the disease. A paradigm change for osteoporosis therapy requires an advanced understanding of such changes to establish the efficacy of osteocyte-targeted therapies to inhibit resorption and secondary mineralization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.